P&K Skin Research Center Co. Ltd (347740) - Total Liabilities

Latest as of September 2025: ₩4.49 Billion KRW ≈ $3.04 Million USD

Based on the latest financial reports, P&K Skin Research Center Co. Ltd (347740) has total liabilities worth ₩4.49 Billion KRW (≈ $3.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 347740 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

P&K Skin Research Center Co. Ltd - Total Liabilities Trend (2018–2024)

This chart illustrates how P&K Skin Research Center Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see P&K Skin Research Center Co. Ltd total assets.

P&K Skin Research Center Co. Ltd Competitors by Total Liabilities

The table below lists competitors of P&K Skin Research Center Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Phoenix Materials Co. Ltd
KQ:050090
Korea ₩3.30 Billion
Microequities Asset Management Group Ltd
AU:MAM
Australia AU$4.50 Million
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
Turkey TL931.18 Million
K-One Technology Bhd
KLSE:0111
Malaysia RM74.92 Million
Rossmax International Ltd
TWO:4121
Taiwan NT$2.22 Billion
Panorama Sentrawisata Tbk
JK:PANR
Indonesia Rp724.87 Billion
Namuga Co. Ltd
KQ:190510
Korea ₩67.70 Billion
Mega Matrix Corp.
NYSE MKT:MPU
USA $4.36 Million

Liability Composition Analysis (2018–2024)

This chart breaks down P&K Skin Research Center Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See P&K Skin Research Center Co. Ltd (347740) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how P&K Skin Research Center Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for P&K Skin Research Center Co. Ltd (2018–2024)

The table below shows the annual total liabilities of P&K Skin Research Center Co. Ltd from 2018 to 2024.

Year Total Liabilities Change
2024-12-31 ₩5.10 Billion
≈ $3.46 Million
+61.14%
2023-12-31 ₩3.17 Billion
≈ $2.15 Million
-15.13%
2022-12-31 ₩3.73 Billion
≈ $2.53 Million
-7.31%
2021-12-31 ₩4.03 Billion
≈ $2.73 Million
-5.59%
2020-12-31 ₩4.27 Billion
≈ $2.89 Million
+22.85%
2019-12-31 ₩3.47 Billion
≈ $2.35 Million
+106.29%
2018-12-31 ₩1.68 Billion
≈ $1.14 Million
--

About P&K Skin Research Center Co. Ltd

KQ:347740 Korea Diagnostics & Research
Market Cap
$33.39 Million
₩49.27 Billion KRW
Market Cap Rank
#23460 Global
#1603 in Korea
Share Price
₩1706.00
Change (1 day)
-1.10%
52-Week Range
₩1630.00 - ₩2800.00
All Time High
₩7272.32
About

P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vi… Read more